This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

Azithromycin shows promise for putting asthma into remission

respiratory virus
Credit: Pixabay/CC0 Public Domain

Researchers at HMRI and the University of Newcastle have evaluated a drug called azithromycin, a macrolide antibiotic, to test if it would put moderate to severe asthma into remission.

Professor Peter Gibson from the HMRI Asthma and Breathing program says the findings were very promising.

"Remission in adults with asthma is a relatively new concept and a less researched area but it has recently gained attention. Recent studies have found that is possible in severe asthma treated with highly effective biologics therapies, a new class of drugs," Professor Gibson said.

"We've taken a different approach by testing another type of drug. We're the only people in the world to have tested this drug and we have confirmed that remission can be achieved in up to 50 percent of moderate to severe asthma patients treated with long-term azithromycin," Professor Gibson said.

These findings are published in the journal Chest.

"This is the first study reporting remission can be achieved using drugs other than biologics. Biologics are injection medicines, cost-prohibitive in low- and (approx. $500 to $3000/month) and restricted to most severe cases in high-income countries.

"Azithromycin—the drug we tested—is a low-cost oral therapy (approximately $15/week) and a guideline-recommended treatment for moderate to . So, these findings have numerous implications," lead author, Dr. Dennis Thomas, said.

"Achieving remission has huge health and as exacerbations are completely abolished, symptoms are fully under control, and the need for risky drugs such as corticosteroids is totally eliminated. Future asthma treatment should aim to achieve asthma remission," Dr. Thomas said.

The team is working towards developing the next-generation asthma management strategy and defining the future frontiers in asthma under the umbrella of a large research program called the FUTURE program.

More information: Dennis Thomas et al, Azithromycin Induced Asthma Remission in Adults With Persistent Uncontrolled Asthma, Chest (2024). DOI: 10.1016/j.chest.2024.02.048

Journal information: Chest
Citation: Azithromycin shows promise for putting asthma into remission (2024, May 6) retrieved 18 July 2024 from https://medicalxpress.com/news/2024-05-azithromycin-asthma-remission.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Leading asthma groups tackle definition of clinical remission in treatment of asthma

0 shares

Feedback to editors